". J. Brit Will" D. Q.L. LAY 2006

1103326-0900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

: Johansson et al. : 10/560,319

Serial No. Filed

: December 9, 2005

For

: New Azetidine Compounds

Examiner

: TBA

Group Art Unit : TBA

Certificate of Mailing Under 37 C.F.R. § 1.8

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to: Assistant Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450

Andrew Fessak 48,528

Agent Name PTO Reg. No.

Mail Stop PCT Commissioner for Patents Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit this communication in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. Favorable consideration of the documents cited on the attached Form PTO/SB/08A is respectfully requested.

The referenced application is the U.S. national stage application of international application no. PCT/SE2004/000901, filed June 9, 2004 (the "PCT application"). The documents identified on the attached Form PTO/SB/08A include documents cited in the specification and/or the International Search Report ("ISR") which issued in connection with the PCT application. Copies of the published PCT application, i.e., International Publication

Serial No. 10/560,319, filed Dec. 9, 2005

Docket No. 1103326-0900

Page 2 of 2

Number WO 2004/110344, and the ISR were previously submitted on December 9, 2005 with the national stage application transmittal documents.

Copies of Cited U.S. Patent Documents are Not Provided

As announced in the Official Gazette of August 5, 2003, the requirement under 37 CFR 1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003 has been waived.

Accordingly, copies of the U.S. patents and/or published patent applications cited on the attached Form PTO/SB/08A are not provided with this Information Disclosure Statement.

Time of Transmittal of Information Disclosure Statement

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b)(3) before the mailing date of the first Office Action on the merits and, therefore, no fee should be due. However, if any fee is required, the Assistant Commissioner is authorized to charge such fee to Deposit Account No. 23-1703.

Dated: (1941) 26,2006

Respectfully submitted,

Andrew Fessak Reg. No. 48,528

Customer No. 007470 White & Case LLP

Direct Dial: (212) 819-8437

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known			
Substitute for form 1449/17 TO		Application Number	10/560,319	
INFORMATION DISCLOSURE	UDE	Filing Date	December 9, 2005	
		First Named Inventor	Johansson et al.	
STATEMENT DI ATTECANT		Art Unit	TBA TBA	
		Examiner Name		

(Use as many sheets as necessary)			Exam	Examiner Name TBA			
Sheet	1 of 1		Atto	orney Docket Number 11		103326-0900	
		S. PATENT D					
Examiner Cite Initials No.	Document Number Number-Kind Code ^{2 (glassum)}	Publication MM-DD-Y		Name of Patentee Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages/Figures Appear	
/KH/	US-6,013,652	01-11-20		Maccoss et al.		Relevant rassages/rigures Ap	pear
	00 01010100	011120	-				
					\neg		_
		IGN PATEN					
Examiner Cite Initials No.	Foreign Patent Document		Publication Date Na MM-DD-YYYY A			Pages, Columns, Lines, Where	1
	Country Code3-Number4-Kind Code5((Chrown)		- 1 7 7 7	Applicant of Cited Document		Relevant Passages Or Relevant Figures Appear	T ⁶
/KH/	EP-962,457-B1	12-08-	1999	Fox et al.			
	EP-791,592-B1	08-27-	1997	Mackenzie et al.	_		-
	EP-790-248-B1	08-20-	1997	Mackenzie et al.			\vdash
	EP-630,887-A1	12-28-	1994	Jacobs et al.			\vdash
	EP-625,509-B1	11-23-	1994	Jacobs et al.			
	EP-625,509-A1	11-23-	1994	Jacobs et al.			\vdash
	WO-03/37889-A1	05-08-	2003	Bialecki et al.			┢
	WO-02/51807-A1	07-04-	2002	Shenvi			Т
	WO-00/34243	06-15-	2000	Ohnmacht			\vdash
	WO-00/25766	05-11-	2000	Lengel et al.			Н
	WO-00/20389	04-13-	2000	Bernstein et al.			
	WO-00/20003	04-13-	2000	Bernstein et al.			\vdash
	WO-00/02859	01-20-	2000	Bernstein et al.			
	WO-99/01451	01-14-	1999	Alker et al.			
	WO-97/27185	07-31-	1997	Mackenzie et al.			
	WO-97/25322	07-17-	1997	Mackenzie et al.			Г
	WO-96/24582	08-15-	1996	Bernstein et al.			Г
	WO-96/10568	04-11-	1996	Chiang et al.			Т
	WO-96/05193	02-22-	1996	Mackenzie et al.			
	WO-95/15691	06-15-	1995	Gamblin et al.			匚
	WO-95/12577	05-11-	1995	Miller			
W	WO-95/05377	02-23-	1995	Miller			
					\perp		
				DOCUMENTS			
Examiner Cite Initials No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
/KH/	"4-Amino-2-(aryl)-butylbenzar Antagonists of the Human Neu Lett., Volume 13, Number 13,	rokinin-2 (NK	2) Rec	eptor", Mackenzie et	al., Bi	ioorg. Med. Chem.	
Examiner Signature	/Kahsay Habte/			Date Considered		02/21/2008	_

DLUMON: Multi of these conditions, which or an elicide is in conformant to in PSP 80. Due for drught defined for an excellent and an excellent behind to yet of the first with an exercision to supplice. 'Applicant's behinding the conformant of the